Last reviewed · How we verify
Continue Ritonavir-boosted PI+Rosuvastatin
This combination uses ritonavir-boosted protease inhibitor antiretroviral therapy to suppress HIV replication, while rosuvastatin reduces cholesterol levels to manage cardiovascular risk in HIV-positive patients.
This combination uses ritonavir-boosted protease inhibitor antiretroviral therapy to suppress HIV replication, while rosuvastatin reduces cholesterol levels to manage cardiovascular risk in HIV-positive patients. Used for HIV-1 infection in treatment-experienced or treatment-naive patients, Hyperlipidemia/cardiovascular risk reduction in HIV-positive patients on protease inhibitor therapy.
At a glance
| Generic name | Continue Ritonavir-boosted PI+Rosuvastatin |
|---|---|
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination (protease inhibitor + statin) |
| Target | HIV protease (PI component); HMG-CoA reductase (rosuvastatin component) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ritonavir-boosted protease inhibitors (PIs) block HIV protease, preventing viral maturation and reducing viral load in HIV-infected individuals. Rosuvastatin is a statin that inhibits HMG-CoA reductase to lower LDL cholesterol. This combination addresses both HIV infection and the elevated cardiovascular risk associated with HIV and certain antiretroviral regimens.
Approved indications
- HIV-1 infection in treatment-experienced or treatment-naive patients
- Hyperlipidemia/cardiovascular risk reduction in HIV-positive patients on protease inhibitor therapy
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea)
- Elevated liver enzymes
- Myalgia or muscle pain (statin-related)
- Lipid abnormalities
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continue Ritonavir-boosted PI+Rosuvastatin CI brief — competitive landscape report
- Continue Ritonavir-boosted PI+Rosuvastatin updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI